For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Drug delivery technologies play an increasingly important role in the drug-development process as a means to improve the efficacy of a drug, make a drug safer, more effective, or convenient, extend its patent life, or differentiate it in the marketplace. The global advanced drug delivery systems market in terms of revenue is set to grow by US$ 74 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 5.1% during the forecast period, according to data and analytics company StrategyHelix. Growth in the geriatric population, increasing prevalence of chronic diseases, increase in average income, rising demand for healthcare, rising demand for effective drug delivery design are the key factors driving market growth.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for advanced drug delivery systems. The global advanced drug delivery systems market is segmented on the basis of type, drug delivery carrier, application, and region. By type, it is categorized into oral drug delivery, injection-based drug delivery, inhalation/pulmonary drug delivery, transdermal drug delivery, transmucosal drug delivery, and others. The oral drug delivery segment held the largest market share in 2020. By drug delivery carrier, the advanced drug delivery systems market is divided into nanoparticles, monoclonal antibodies, liposomes, prodrugs, microparticles, dendrimer, and others. The nanoparticles segment accounted for the largest market share in 2020. Based on application, the advanced drug delivery systems market is divided into cardiovascular, central nervous system (CNS), diabetes, inflammatory & allergies, oncology, ophthalmic, respiratory, urology, and others.
The report has profiled some of the key players of the market such as Abbott Laboratories, Amgen Inc., AstraZeneca plc, Baxter International Inc., Bayer HealthCare Pharmaceuticals Inc., Boston Scientific Corporation, F. Hoffmann-La Roche AG, GlaxoSmithKline plc., Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the advanced drug delivery systems market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: oral drug delivery, injection-based drug delivery, inhalation/pulmonary drug delivery, transdermal drug delivery, transmucosal drug delivery, and others
Drug delivery carrier: nanoparticles, monoclonal antibodies, liposomes, prodrugs, microparticles, dendrimer, and others
Application: cardiovascular, central nervous system (CNS), diabetes, inflammatory & allergies, oncology, ophthalmic, respiratory, urology, and others
Region: North America, Asia Pacific, Europe, and Rest of the World (ROW)
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the global advanced drug delivery systems market
Identify regional strategies and strategic priorities on the basis of local data and analysis
Pinpoint growth sectors and trends for investment
Understand what the future of the global advanced drug delivery systems market looks like
Identify the competitive landscape and window of opportunity